Gsa Capital Partners LLP Sage Therapeutics, Inc. Transaction History

Gsa Capital Partners LLP

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 15, 2024	BUY	$10.58 - $17.9 $709,854 - $1.2 Million	67,094 Added 575.67%	78,749 $855,000
Q1 2024 May 03, 2024	SELL	$18.62 - $26.95 $1.09 Million - $1.58 Million	-58,724 Reduced 83.44%	11,655 $218,000
Q4 2023 Feb 16, 2024	BUY	$17.1 - $22.26 $1.2 Million - $1.57 Million	70,379 New	70,379 $1.53 Million
Q1 2023 May 12, 2023	BUY	$37.27 - $46.57 $399,571 - $499,276	10,721 New	10,721 $449,000
Q3 2022 Nov 14, 2022	SELL	$32.28 - $43.27 $167,630 - $224,701	-5,193 Reduced 27.7%	13,557 $531,000
Q2 2022 Aug 09, 2022	BUY	$27.52 - $37.99 $516,000 - $712,312	18,750 New	18,750 $606,000
Q1 2022 May 11, 2022	SELL	$30.71 - $45.71 $799,534 - $1.19 Million	-26,035 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$37.06 - $47.11 $654,627 - $832,151	17,664 Added 211.01%	26,035 $1.11 Million
Q3 2021 Nov 12, 2021	SELL	$40.26 - $57.37 $362,742 - $516,903	-9,010 Reduced 51.84%	8,371 $371,000
Q2 2021 Aug 05, 2021	BUY	$54.88 - $79.29 $953,869 - $1.38 Million	17,381 New	17,381 $987,000
Q1 2021 May 10, 2021	SELL	$70.65 - $96.76 $458,306 - $627,682	-6,487 Closed	0 $0
Q4 2020 Feb 03, 2021	BUY	$58.41 - $89.06 $101,808 - $155,231	1,743 Added 36.74%	6,487 $561,000
Q3 2020 Nov 06, 2020	BUY	$41.13 - $62.45 $195,120 - $296,262	4,744 New	4,744 $290,000
Q2 2020 Aug 11, 2020	SELL	$25.95 - $43.15 $554,655 - $922,288	-21,374 Closed	0 $0
Q1 2020 May 12, 2020	BUY	$26.15 - $77.24 $397,663 - $1.17 Million	15,207 Added 246.59%	21,374 $614,000
Q4 2019 Feb 12, 2020	BUY	$60.18 - $154.77 $371,130 - $954,466	6,167 New	6,167 $445,000

198

46.5M

402K

209K

Ticker SAGE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,422,300
Market Cap $323M
Description
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

Stay updated on Gsa Capital Partners LLP with notifications on news.